Tigecycline Basics and Liver Metabolism
Tigecycline, a glycylcycline antibiotic used for complicated infections, is primarily eliminated via biliary excretion and hepatic metabolism, bypassing much renal clearance. This makes it prone to accumulation in patients with liver impairment.[1]
Dosage Adjustments for Liver Problems
- Child-Pugh A (mild impairment): No adjustment needed; standard 100 mg loading dose followed by 50 mg every 12 hours.
- Child-Pugh B (moderate): Reduce to 100 mg loading, then 25 mg every 12 hours.
- Child-Pugh C (severe): 100 mg loading, then 25 mg every 24 hours. Monitor closely due to higher exposure risks.[2][3]
Key Interaction Risks with Pre-Existing Liver Issues
Tigecycline elevates liver enzymes (ALT/AST) in up to 25-30% of patients, with severe cases (including hepatitis or failure) in 1-2%. Pre-existing liver disease amplifies this:
- Increased AUC (drug exposure) by 2-3x in moderate/severe impairment raises hepatotoxicity odds.
- Avoid in acute liver failure or decompensated cirrhosis; use only if benefits outweigh risks.
- Symptoms to watch: jaundice, nausea, dark urine—discontinue if transaminases exceed 5x upper normal limit.[2][4]
Clinical Evidence from Trials
In phase 3 studies, discontinuations due to liver events were 1-3% overall, but higher (up to 5%) in those with baseline elevations. Post-marketing reports link it to rare cholestatic injury, especially in combo with other hepatotoxins like valproate.[3][5]
Monitoring and Alternatives
Check baseline LFTs, monitor weekly during treatment. Alternatives for liver-compromised patients include less hepatotoxic options like meropenem or linezolid, depending on infection site.[2]
When Patents Expire (Generic Availability)
U.S. patents on tigecycline (Tygacil) expired in 2021-2022, enabling generics that maintain the same liver warnings—no formulation changes alter interactions.[6]
[1] FDA Tygacil Label
[2] Tygacil Prescribing Information
[3] Hepatic Impairment Study (MSD Data)
[4] LiverTox Database - Tigecycline
[5] Adverse Event Reporting System (FAERS)
[6] DrugPatentWatch - Tygacil